Anemia of Chronic Disease Clinical Trial
Official title:
Phase IIa Study to Characterize the Effects of the Spiegelmer® NOX H94 on Anemia of Chronic Disease in Patients With Cancer
This study is conducted to determine the safety, tolerability, and efficacy of NOX-H94 in
patients with anemia of chronic disease (ACD). Furthermore, this study is intended to
provide data needed to correlate plasma concentrations of NOX-H94 with its efficacy and to
choose the appropriate dose and dose schedule of subsequent efficacy studies.
Some chronic diseases, e.g. tumors, inflammation, renal disease, are associated with high
hepcidin concentrations in the blood. These hepcidin concentrations cause a reduction in
iron concentrations in the blood and subsequently impair formation of red blood cells.
Treatment with NOX-H94 is expected to inhibit this patho-mechanism by binding and
inactivating hepcidin.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
| Completed |
NCT01988116 -
Effects of Vitamin D Replacement on Hormones Regulating Iron Metabolism in Individuals With Chronic Kidney Disease
|
Phase 0 | |
| Terminated |
NCT01873534 -
A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD
|
Phase 2 | |
| Not yet recruiting |
NCT01846689 -
An Open-label Trial to Determine Increased Red Blood Cell Production in Subjects With Anemia of Chronic Disease
|
Phase 3 | |
| Terminated |
NCT03528564 -
Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia
|
Phase 2 | |
| Completed |
NCT01522794 -
Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model
|
Phase 1 | |
| Not yet recruiting |
NCT04071067 -
Anemia of Inflammation and Deficiency Anemia
|